Cargando…

Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease

OBJECTIVE: Changes in the care of patients with SLE dictate a re-evaluation of its natural history and risk factors for disease deterioration and damage accrual. We sought to decipher factors predictive of a deterioration in phenotype (‘transition’) in patients initially presenting with non-severe d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikolopoulos, Dionysis S, Kostopoulou, Myrto, Pieta, Antigoni, Flouda, Sofia, Chavatza, Katerina, Banos, Aggelos, Boletis, John, Katsimbri, Pelagia, Boumpas, Dimitrios T, Fanouriakis, Antonis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326262/ https://www.ncbi.nlm.nih.gov/pubmed/32601172 http://dx.doi.org/10.1136/lupus-2020-000394

Ejemplares similares

Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort
por: Nikolopoulos, D, et al.
Publicado: (2020)

Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management
por: Nikolopoulos, Dionysis, et al.
Publicado: (2019)

Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy
por: Nikolakis, Dimitrios, et al.
Publicado: (2023)

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
por: Nikoloudaki, Myrto, et al.
Publicado: (2023)

ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus
por: Manolakou, Theodora, et al.
Publicado: (2022)

Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the “Attikon” Lupus Cohort
por: Nikolopoulos, Dionysis, et al.
Publicado: (2022)

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
por: Kostopoulou, Myrto, et al.
Publicado: (2020)

Interstitial Pneumonia with Autoimmune Features (IPAF): A Single-Centre, Prospective Study
por: Karampeli, Maria, et al.
Publicado: (2020)

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus
por: Adamichou, Christina, et al.
Publicado: (2021)

A network-based approach reveals long non-coding RNAs associated with disease activity in lupus nephritis: key pathways for flare and potential biomarkers to be used as liquid biopsies
por: Sentis, George, et al.
Publicado: (2023)

Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
por: Grigoriou, Maria, et al.
Publicado: (2020)

Advances in Systemic Lupus Erythematosus (SLE): A case for optimism
por: Fanouriakis, Antonis, et al.
Publicado: (2017)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis
por: Frangou, Eleni, et al.
Publicado: (2022)

Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015
por: Hammond, Edward R, et al.
Publicado: (2021)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
por: Alunno, Alessia, et al.
Publicado: (2019)

Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus
por: Adamichou, Christina, et al.
Publicado: (2020)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015
por: Jiang, Miao, et al.
Publicado: (2021)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Changing paradigms in the treatment of systemic lupus erythematosus
por: Fanouriakis, Antonis, et al.
Publicado: (2019)

Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022)

Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus
por: Fanouriakis, Antonis, et al.
Publicado: (2019)

Mitophagy Balance in Various Cell Subsets in Patients with ANCA-Associated Vasculitis and Correlation with the Presence of Anti-Neutrophil Cytoplasmic Antibodies
por: Banos, Aggelos, et al.
Publicado: (2020)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Systemic Lupus Erythematosus and COVID-19
por: Pappa, Maria, et al.
Publicado: (2023)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2021)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021)

Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus
por: Yoshida, Tsuneyasu, et al.
Publicado: (2022)

Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study
por: Sada, Ken-ei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dd7ri67t4llt0er3m3raarldg9